Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, capturing more than double the market share of its rival two months after launch. But ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results